

AXIRON NOW AVAILABLE IN BRAZIL

Acrux (ASX: ACR) today confirmed that Axiron® is now being distributed by Eli Lilly and Company in Brazil for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The product is being sold in Brazil under the trademark Axeron.

Acrux Executive Chairman Ross Dobinson commented “We are pleased that Lilly has achieved another milestone in the international commercialisation of Axiron, which is already available to patients in the United States, Australia and Canada and which also recently received approval in Germany.

Contact

Ross Dobinson, Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including AXIRON®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.